POSEDEL RHEA J sold $836K of AEHR (indirect holdings)

POSEDEL RHEA J (Director) sold 5,973 indirectly-held shares of AEHR TEST SYSTEMS (AEHR) at $140.00 ($0.84M total) on 2026-08-14.

Original reporting
SEC EDGAR · POSEDEL RHEA J
Published Aug 14, 2026, 9:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AEHR
Neutral
medium confidence
Mentioned
$AEHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEHRNeutralLow
01

Why it matters

The disclosed sale provides incremental sentiment information but no new information about AEHR’s business performance, guidance, or risk factors.

02

Market read

Traders may monitor for follow-on insider activity, but this single Form 4 sale is not a standalone catalyst.

03

What to watch

The filing notes the sale was indirect and does not state a 10b5-1 plan; traders may over-interpret intent without knowing tax, diversification, or pre-existing arrangements.

Relevance 5/10Novelty 3/10Timing: Filed on 2026-08-14, reflecting an insider sale executed the same day.

Background

The article is a SEC Form 4 insider transaction disclosure for AEHR, listing the director’s role and the details of an open-market sale.

Company-level read

Ticker impact

$AEHRNeutralMedium confidence
Context

Director POSEDEL RHEA J sold 5,973 shares of AEHR on 2026-08-14 for about $836,220, reported as an indirect open-market sale.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing discloses the transaction size, price ($140/share), and that it was an open-market sale with no 10b5-1 plan stated. However, insider sales are common and the article provides no new operational, financial, or regulatory catalyst.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity management and does not necessarily signal reduced confidence, especially without any accompanying negative company news.

Key entities

  • AEHR

    AEHR Test Systems, the issuer of the Form 4 insider transaction.

  • POSEDEL RHEA J

    Director of AEHR who sold shares via an indirect open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AEHRHighAI 9/10

Aehr Test Systems (AEHR) (Q1 2027) Earnings Call Highlights: Record Revenue, Raised

Aehr Test Systems (AEHR) reported record Q1 2027 revenue of $33M and raised annual guidance to $150M. CEO Gayn Erickson highlighted a potential large burn-in opportunity, estimating $35M-$70M in revenue per million units shipped. The company expects sequential growth in remaining quarters, with Q4 potentially the highest. Management confirmed they are not supply-constrained and can ship more than guided. Silicon carbide revenue was about $10M in fiscal 2026, with expectations for growth in 2027.

$AEHRHighAI 9/10

AEHR Stock Surges After Massive AI-Driven Earnings Beat

Aehr Test Systems (AEHR) stock rose 26.6% after reporting Q1 FY27 revenue of $33M, up 300% year-over-year and 75% quarter-over-quarter. Adjusted EPS was $0.28, beating estimates. The company raised FY27 revenue guidance to $150M, citing strong demand for AI and power semiconductor testing.

$AEHRHighAI 9/10

Aehr Stock Jumps 16% After Bookings Hit $46.7 Million

Aehr Test Systems (AEHR) shares rose 16.38% premarket after its Q1 revenue tripled to $33.0M, beating estimates. The company raised its full-year outlook to $150M, citing strong bookings and backlog growth. CEO Gayn Erickson highlighted a major AI customer opportunity. According to GuruFocus, there are 6 warning signs with AEHR.

$AEHRHighAI 8/10

Why is Aehr Test Systems stock surging today?

Aehr Test Systems (AEHR) stock surged 18.8% in pre-market trading after reporting record Q1 2027 revenue of $33.0M, up 200% YoY, and raising full-year revenue outlook to $150M. Non-GAAP net income was $9.4M, or $0.28 per share, exceeding analyst estimates. The company cited strong demand for AI semiconductor test solutions and a book-to-bill ratio of 1.4.

$AEHRMed

Aehr stock jumps on beat and raise amid AI demand

Aehr Test Systems (AEHR) shares rose 15% after reporting Q1 revenue of $33M, up 200% YoY, and raising its FY2027 outlook to $150M. The company cited strong demand for its semiconductor testing systems used in AI chips. CEO Gayn Erickson noted a conservative approach to the revised target. Bookings were $46.7M with a book-to-bill ratio of 1.4.